Given that satisfactory survival rates have been achieved by PD-1 inhibitors plus apatinib in patients with advanced cancer (30, 31), it could be assumed that patients with advanced CRC may have better survival outcomes after treatment with PD-1 inhibitors plus apatinib. This evidence concerns the gene PDCD1 and cancer.